Carl Novina, MD, Ph.D., has been appointed as scientific advisor, Atossa Genetics Inc. a clinical-stage pharma company developing novel therapeutics and delivery methods for breast cancer.

Dr. Novina is a leading researcher in the field of RNAi therapeutics. He is an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT. He is currently the principal investigator of the Novina Lab at the Dana-Farber Cancer Institute. His laboratory has made several important discoveries into the biology of noncoding RNAs, their dysregulation in cancers, and their development as biomedical tools.

“We are delighted to welcome Dr. Novina to our Scientific Advisory Board which is composed of world-class experts in Breast Cancer research,” said Dr. Steve Quay, president and chief executive officer of Atossa Genetics. “Dr. Novina’s immunology expertise will be invaluable as we develop our proprietary microcatheters for delivery of CAR-T cell therapies for the treatment of the deadlier forms of breast cancer.”